ACE inhibitors in heart failure: an update

Area of Science:

• Cardiology
• Pharmacology

Background:

• Angiotensin-converting enzyme (ACE) inhibitors are standard in heart failure management, yet optimal dosing remains debated.
• Despite proven benefits, morbidity and mortality in heart failure patients remain high.
• Evidence suggests ACE inhibitors benefit patients with both impaired and preserved systolic function.

Purpose of the Study:

• To evaluate the efficacy of high versus low dose ACE inhibition in heart failure patients (ATLAS trial).
• To assess the role of ACE inhibitors in patients post-myocardial infarction with varying systolic function (AIRE study).
• To clarify the benefits of ACE inhibitors in high-risk cardiovascular patients, including those with preserved systolic function (HOPE trial).

Main Methods:

• Comparison of high-dose versus low-dose ACE inhibition.
• Analysis of heart failure patients post-myocardial infarction, assessing systolic function.
• Evaluation of ACE inhibitor ramipril in high-risk cardiovascular patients without known systolic dysfunction.

Main Results:

• The ATLAS trial yielded equivocal findings on high vs. low dose ACE inhibition.
• The AIRE study demonstrated long-term benefit of ACE inhibition post-myocardial infarction, irrespective of systolic function.
• The HOPE trial showed ramipril significantly reduced cardiovascular death, stroke, and myocardial infarction by 20% in high-risk patients.

Conclusions:

• ACE inhibitors play a pivotal role in managing heart failure and preventing myocardial infarction, particularly in patients with underlying ischemic heart disease.
• Benefits of ACE inhibitors extend to patients with preserved systolic function.
• Further research is needed to compare ACE inhibitors with angiotensin antagonists and explore combination therapies.